Immunitybio Inc faces market pressure as shares decline amid investor concerns.
Immunitybio Inc (NASDAQ:IBRX) is seeing a significant drop in its stock price, down 3.00% today. This decline comes as the company gears up for the Piper Sandler Virtual Oncology Symposium, raising questions about its current valuation and how the market views it.
Advertisement
Immunitybio Inc
IBRX.US
IBRX.US
Immunitybio Inc
WealthAwesomeMarket cap
$11.14B
52W high
$12.43
52W low
$1.95
1W change
+2.19%
Beta
0.03
Analyst Price Targets
Based on 4 analysts covering IBRX · as of Oct 7, 2026
Wall Street analysts forecast IBRX stock price to rise 21.3% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
C$12.75
+21.3% Upside
Previously C$13.00 on Oct 5, 2026
Current Price
C$10.51
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IBRX's historical volatility
30-Day Vol
69.1%
Annualized
90-Day Vol
66.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$12.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.15 | C$8.79 – C$14.16 |
| 60 trading days | C$11.84 | C$8.45 – C$16.59 |
| 90 trading days | C$12.56 | C$8.31 – C$18.99 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Immunitybio's upcoming presentations and data releases, as these could greatly influence the stock's direction in the near future.
3.00% decline in Immunitybio's stock today
The stock's recent performance shows a change in investor sentiment, with growing concerns about valuation and competitive pressures.
Bull case
Immunitybio has a promising pipeline of immunotherapy products that could drive significant growth if clinical trials produce positive results.
Bear case
The recent drop in stock price reflects increasing doubts about Immunitybio's ability to achieve its ambitious growth targets and the potential regulatory challenges it may face.
Advertisement
Market Reaction to Upcoming Symposium
Immunitybio is preparing to participate in the Piper Sandler Virtual Oncology Symposium, a venue where biotech companies often share important data. However, the current market reaction indicates that investors are cautious about the company's ability to meet high expectations. The 3.00% decline today suggests that traders are reevaluating the risks linked to Immunitybio's pipeline.
Valuation Concerns Amidst Competitive Pressures
Although some analysts consider Immunitybio potentially undervalued, the recent stock performance raises questions about its current valuation. With a year-to-date return of 382.67%, the market has already factored in a lot of optimism. However, as competitors emerge and regulatory challenges arise, investors might be reassessing their positions, contributing to today's decline.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
